Potential anti-diabetic applications of a new molecule with affinity for β3-adrenoceptors

Life Sciences

Volumn 59, Issue 11, 1996, Pages

  Barrionuevo, Meritxell ^a   Milagro, Fermín I ^a   Cenarruzabeitia, Edurne ^a   Martínez, J Alfredo ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Diabetes; Hypoglycemia; Lipomobilization; Oxygen consumption; 3 adrenergic agonists

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ALLOXAN; ANTIDIABETIC AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOSE; INSULIN; ISOPRENALINE; METHACHOLINE; NEW DRUG; ORCIPRENALINE; RECEPTOR SUBTYPE; TRECADRINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; ESOPHAGUS MUSCLE; FEMALE; GUINEA PIG; HEART; HYPOGLYCEMIA; INSULIN RELEASE; LIPID METABOLISM; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR AFFINITY; SMOOTH MUSCLE RELAXATION; TRACHEA;

ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 0010038975     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(96)00395-5     Document Type: Article

References (17)

1. 1. J. R. S. ARCH, Pharmacol. Comm. 6 223-228 (1995).
2. 2. L. J. EMORINE, S. MARULLO, M.M. BRIEND-SUTREN, G. PATEY, K. TATE, C. DELAVIER-KLUTCHKO,and A:D. STROSBERG, Science 245 1118-1121 (1989)
3. 3 R. HOWE, Drugs Fut. 18 529-549 (1993).
4. 4 D. E. BERKOWITZ, N. A. NARDONE, R. M. SMILEY, D. T. PRICE, D. K. KREUTTER, R. T. FREMEAU, and D. A. SCHWINN, Eur. J. Pharmacol. 289 223-228 (1995).
5. 5 T. YOSHIDA, N. SAKANE, Y. WAKABAYASHI, T. UMEKAWA and M. KONDO, Life. Sci. 54 491-498 (1994).
6. 6 T. YOSHIDA, N. HIRAOKA,and M. KORDO, Endocrinol. Japan. 38 641-646 (1991).
7. 7 N. ROCHET, J.F. TANTI, T. GREMEAUX, E. VAN OBBERGHEN, and T. LE MARCHAND-BRUSTEL, Am. J Physiol. 255 E101-109 (1988).
8. 8 S. A. SMITH, A. L. LEVY, M. V. SENNITT, D. L. SIMPSON, and M. A. CAWTHORNE, Biochem. Pharmacol. 34 2425-2429 (1985).
9. 9 M. A CAWTHORNE, M. V. SENNITT, J. R. S. ARCH, S. A. SMITH, Am. J. Clin. Nutr. 56 252-275 (1992).
10. 10 R. E. P. DE BOER, F. BROUWER, and J. ZAAGSMA, Br. J. Pharmacol. 110 442-446 (1993).
11. 11 E. CASTIELLA, D. FRECHILLA, B. LASHERAS, E. CENARRUZABEITIA, J. J. MARTINEZ DE IRUJO, E. ALBERDI, E. SANTIAGO, A. MONGE, A. VILLANUEVA, F. J. MARTINEZ, and M. FONT, J. Pharm. Pharmacol. 47 601-607 (1995).
12. 12 J. CORTIJO, J. BOU, J. BELETA, I. CARDELUS, J. LLENASA, E. MORCILLO, and R. W. GRISTWOOD, Br. J. Pharmacol. 108 562-568 (1993).
13. 13 J. B. HENRY, Todd-Sandford-Davidsohn: Clinical diagnosis and management by laboratory methods, W. B. Saunders Company (Ed.), Philadelphia (1988).
14. 14 M. J. STOCK, and D. K. SUDERA, Br. J. Pharmacol. 95 741P (1988).
15. 15 G. J. MURPHY, D. M. KIRKHAM, M. A. CAWTHORNE, and P. YOUNG, Biochem. Pharmacol. 46 575-581 (1993).
16. 16 J. A. MARTINEZ, B. BERRAONDO, R. PEREZ, G. FRÜHBECK, and M. P. FERNANDEZ-OTERO., FASEB J. 10 A504 (1996).
17. 17 M. P. PORTILLO, A. S. DEL BARRIO, M. A. GARCIA-CALONGE, and J. A. MARTINEZ, Life. Sci. 58 405-414 (1996).